<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.2//EN" "ep-patent-document-v1-2.dtd">
<ep-patent-document id="EP01959921B8W1" file="EP01959921W1B8.xml" lang="en" country="EP" doc-number="1276738" kind="B8" correction-code="W1" date-publ="20080220" status="c" dtd-version="ep-patent-document-v1-2">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTR............................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>DIM360 Ver 2.4  (29 Nov 2007) -  2999001/0</B007EP></eptags></B000><B100><B110>1276738</B110><B120><B121>CORRECTED EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B8</B130><B132EP>B1</B132EP><B140><date>20080220</date></B140><B150><B151>W1</B151><B153>73</B153><B155><B1551>de</B1551><B1552>Bibliographie</B1552><B1551>en</B1551><B1552>Bibliography</B1552><B1551>fr</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>01959921.6</B210><B220><date>20010322</date></B220><B240><B241><date>20021023</date></B241></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>00400800</B310><B320><date>20000323</date></B320><B330><ctry>EP</ctry></B330></B300><B400><B405><date>20080220</date><bnum>200808</bnum></B405><B430><date>20030122</date><bnum>200304</bnum></B430><B450><date>20071212</date><bnum>200750</bnum></B450><B452EP><date>20070615</date></B452EP><B480><date>20080220</date><bnum>200808</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>C07D 401/04        20060101AFI20011002BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>A61K  31/505       20060101ALI20011002BHEP        </text></classification-ipcr><classification-ipcr sequence="3"><text>A61P  25/28        20060101ALI20011002BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>2-AMINO-3-(ALKYL)-PYRIMIDONDERIVATE ALS GSK3.BETA.-HEMMER</B542><B541>en</B541><B542>2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS</B542><B541>fr</B541><B542>DERIVES DU 2-AMINO-3-(ALKYL)-PYRIMIDONE, INHIBITEURS DU GSK3$G(B)</B542></B540><B560><B561><text>WO-A-00/18758</text></B561><B561><text>WO-A-98/24780</text></B561><B561><text>US-A- 4 460 589</text></B561><B562><text>CHEMICAL ABSTRACTS, vol. 84, no. 7, 16 February 1976 (1976-02-16) Columbus, Ohio, US; abstract no. 44112b, page 502; XP002127060 &amp; JP 07 435631 A (KOWA CO., LTD.) 25 September 1974 (1974-09-25)</text></B562><B562><text>CHEMICAL ABSTRACTS, vol. 83, no. 1, 7 July 1975 (1975-07-07) Columbus, Ohio, US; abstract no. 10127z, page 853; XP002127062 &amp; JP 07 435633 A (H. MORI) 25 September 1974 (1974-09-25)</text></B562><B562><text>H. I. SKULNICK ET AL.: "Pyrimidinones. 3. N-Substituted 6-Phenylpyrimidinones and Pyrimidinediones with Diuretic/Hypotensive and Antiinflammatory Activity" J. MED. CHEM., vol. 29, no. 8, 1986, pages 1499-1504, XP000919430</text></B562><B562><text>H. I. SKULNICK ET AL.: "Pyrimidinones. 1. 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-Inducing Antiviral Agents" J. MED. CHEM., vol. 28, no. 12, 1985, pages 1864-1869, XP002127057</text></B562><B562><text>H.-J. KABBE: "Substituierte 4-Hydroxy- und 4-Amino-pyrimidine" LIEBIGS ANN. CHEM., vol. 704, 1967, pages 144-149, XP002127058</text></B562></B560></B500><B700><B720><B721><snm>ALMARIO GARCIA, Antonio</snm><adr><str>26, avenue Roger Salengro</str><city>F-92290 Chatenay Malabry</city><ctry>FR</ctry></adr></B721><B721><snm>ANDO, Ryoichi,
Mitsubishi-Tokyo Pharma. Inc.</snm><adr><str>1000, Kamoshida-cho,
Aoba-ku</str><city>Yokohama-shi,
Kanagawa 227-0033</city><ctry>JP</ctry></adr></B721><B721><snm>ARITOMO, Keiichi,
Mitsubishi-Tokyo Pharma. Inc.</snm><adr><str>1000, Kamoshida-cho,
Aoba-ku</str><city>Yokohama-shi,
Kanagawa 227-0033</city><ctry>JP</ctry></adr></B721><B721><snm>FROST, Jonathan, Reid</snm><adr><str>12, rue du Parc</str><city>F-91320 Wissous</city><ctry>FR</ctry></adr></B721><B721><snm>LI, Adrien, Tak</snm><adr><str>14, rue Pierre Bonnard</str><city>F-92260 Fontenay aux Roses</city><ctry>FR</ctry></adr></B721><B721><snm>SHODA, Aya,
Mitsubishi-Tokyo Pharma. Inc.</snm><adr><str>1000, Kamoshida-cho,
Aoba-ku</str><city>Yokohama-shi,
Kanagawa 227-0033</city><ctry>JP</ctry></adr></B721><B721><snm>UEHARA, Fumiaki,
Mitsubishi-Tokyo Pharma. Inc.</snm><adr><str>1000, Kamoshida-cho,
Aoba-ku</str><city>Yokohama-shi,
Kanagawa 227-0033</city><ctry>JP</ctry></adr></B721><B721><snm>WATANABE, Kazutoshi,
Mitsubishi-Tokyo Pharma. Inc.</snm><adr><str>1000, Kamoshida-cho,
Aoba-ku</str><city>Yokohama-shi,
Kanagawa 227-0033</city><ctry>JP</ctry></adr></B721></B720><B730><B731><snm>Sanofi-Aventis</snm><iid>02783857</iid><irf>SANSYL029/DK</irf><adr><str>174, Avenue de France</str><city>75013 Paris</city><ctry>FR</ctry></adr></B731><B731><snm>Mitsubishi Tanabe Pharma Corporation</snm><iid>08192830</iid><irf>SANSYL029/DK</irf><adr><str>2-10, Dosho-machi 3-chome</str><city>Chuo-ku
Osaka-shi
Osaka 541-8505</city><ctry>JP</ctry></adr></B731></B730><B740><B741><snm>Kugel, Dominique</snm><sfx>et al</sfx><iid>00095671</iid><adr><str>Sanofi-Aventis 
174 avenue de France</str><city>75013 Paris</city><ctry>FR</ctry></adr></B741></B740></B700><B800><B840><ctry>AT</ctry><ctry>BE</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>IE</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LU</ctry><ctry>MC</ctry><ctry>NL</ctry><ctry>PT</ctry><ctry>SE</ctry><ctry>TR</ctry></B840><B844EP><B845EP><ctry>AL</ctry><date>20021023</date></B845EP><B845EP><ctry>LT</ctry><date>20021023</date></B845EP><B845EP><ctry>LV</ctry><date>20021023</date></B845EP><B845EP><ctry>MK</ctry><date>20021023</date></B845EP><B845EP><ctry>RO</ctry><date>20021023</date></B845EP><B845EP><ctry>SI</ctry><date>20021023</date></B845EP></B844EP><B860><B861><dnum><anum>EP2001003640</anum></dnum><date>20010322</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2001070729</pnum></dnum><date>20010927</date><bnum>200139</bnum></B871></B870><B880><date>20030122</date><bnum>200304</bnum></B880></B800></SDOBI>
</ep-patent-document>
